Sign Out
Octreotide has been associated with alteration in nutrient absorption and may have effect the oral absorption of other drugs.
Dose adjustment of medicinal products may be necessary when octreotide is administered concomitantly such as beta blockers, calcium channel blockers, or agents to control fluid and electrolyte balance, cyclosporine, cimetidine, insulin and antidiabetic medicinal products, and bromocriptine.
The caution is advised if octreotide is used concomitantly with drugs with a low therapeutic index that are primarily metabolised by CYP3A4 (e.g. quinidine, terfenadine).
